Alpha 2.0
Login Register
» Authors » Benny Baeten

Benny Baeten

Explore the profile of Benny Baeten including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 177
Followers 0
Related Specialties
Infectious Diseases
Tropical Medicine
General Medicine
Top 10 Co-Authors
Marc Engelen
Fetene Tekle
Ludo Quirynen
Sophie Lachau-Durand
Samuel Wanji
Ermias Diro
Marianne Koschel
Judy Sakanari
Hanna T Sjoberg
Stephen A Ward
Published In
PLoS Negl Trop Dis
Lancet
Antivir Ther
Am J Trop Med Hyg
Affiliations
Soon will be listed here.
Recent Articles
1.
Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds
Hubner M, Ehrens A, Koschel M, Dubben B, Lenz F, Frohberger S, et al.
PLoS Negl Trop Dis . 2019 Jan; 13(1):e0006320. PMID: 30650105
Flubendazole (FBZ) is highly efficacious against filarial nematodes after parenteral administration and presents a promising macrofilaricidal drug candidate for the elimination of onchocerciasis and other filariae. In the present study...
2.
Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi
Fischer C, Ibiricu Urriza I, Bulman C, Lim K, Gut J, Lachau-Durand S, et al.
PLoS Negl Trop Dis . 2019 Jan; 13(1):e0006787. PMID: 30650084
River blindness and lymphatic filariasis are two filarial diseases that globally affect millions of people mostly in impoverished countries. Current mass drug administration programs rely on drugs that primarily target...
3.
Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models
Sjoberg H, Pionnier N, Aljayyoussi G, Metuge H, Njouendou A, Chunda V, et al.
PLoS Negl Trop Dis . 2019 Jan; 13(1):e0006356. PMID: 30650071
The Onchocerca ochengi adult implant and Brugia malayi microfilariemic Severe-Combined Immunodeficient (SCID) mouse models are validated screens to measure macrofilaricidal and microfilaricidal activities of candidate onchocerciasis drugs. The purpose of...
4.
Efficacy and Safety of a Single-Dose Mebendazole 500 mg Chewable, Rapidly-Disintegrating Tablet for and Infection Treatment in Pediatric Patients: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study
Silber S, Diro E, Workneh N, Mekonnen Z, Levecke B, Steinmann P, et al.
Am J Trop Med Hyg . 2017 Oct; 97(6):1851-1856. PMID: 29016336
This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of a new chewable, rapidly-disintegrating mebendazole (MBZ) 500 mg tablet for and infection treatment. Pediatric patients (1-15 years; = 295;...
5.
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients
Lathouwers E, De La Rosa G, Van de Casteele T, Baeten B, Tomaka F, De Meyer S, et al.
Antivir Ther . 2013 Apr; 18(3):289-300. PMID: 23558157
Background: The aim of this analysis was to characterize viral resistance in the Phase III, randomized ODIN trial, which demonstrated non-inferiority of once-daily darunavir/ritonavir (DRV/r) 800/100 mg to DRV/r 600/100...
6.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al.
Lancet . 2007 Jul; 370(9581):39-48. PMID: 17617271
Background: TMC125 (etravirine) is a non-nucleoside reverse-transcriptase inhibitor (NNRTI) with activity against NNRTI-resistant HIV-1 in phase IIb trials. The aim of DUET-2 is to examine the efficacy, tolerability, and safety...